Management of Brain and Leptomeningeal Metastases from Breast Cancer.

摘要: The management of breast cancer (BC) has rapidly evolved in the last 20 years. improvement systemic therapy allows a remarkable control extracranial disease. However, brain (BM) and leptomeningeal metastases (LM) are frequent complications advanced BC represent challenging issue for clinicians. Some prognostic scales designed metastatic have been employed to select fit patients adequate enrollment clinical trials. Different drugs, such as targeted therapies with either monoclonal antibodies or small tyrosine kinase molecules, modified chemotherapeutic agents under investigation. Major aims improve penetration active drugs through blood-brain barrier (BBB) brain-tumor (BTB), establish best sequence timing radiotherapy avoid neurocognitive impairment. Moreover, pharmacologic prevention is new concept driven by efficacy on macrometastases from specific molecular subgroups. This review provide an overview factors involved selection local and/or therapy, well results trials BC. insight promising therapeutic options potential directions future targets against BBB microenvironment discussed.